Catalent Biologics Content

  1. When High-Stakes ADC Decisions Can't Wait for More Material or Better Data 7/21/2026

    Learn how a material-sparing analytical workflow can generate reliable data, reduce dependence on calibration assays, and support faster, more confident candidate evaluation.

  2. Catalent Capabilities Update June 2026: Cell Line Development 6/24/2026

    Discover how an integrated approach to transient expression, cell line development, and manufacturing can accelerate biologics development from gene to IND.

  3. The Analytical Partnership Decisions That Shape ADC Success 6/17/2026

    ADC success depends less on molecular design than on a continuous analytical strategy that connects early characterization to late-stage control, preventing variability, data gaps, and regulatory issues from compounding over time.

  4. Accelerating Antibody Development: A Proven Path From Gene To GMP 6/5/2026

    Discover how an optimized, end-to-end development strategy can help sponsors reach key clinical milestones faster and bring potentially life-saving therapies to patients sooner.

  5. GPEx® Lightning: Stable Cell Line Development For Complex Biologics 6/5/2026

    GPEx® Lightning delivers stable cell pools in 25 days, titers exceeding 15g/L for mAbs and 11g/L for bispecifics, and 60+ generations of stability — compressing timelines by 6–12 weeks.

  6. Madison: Clinical, Commercial Drug Substance Development 6/2/2026

    Catalent Madison offers gene-to-GMP drug substance in 8 months via GPEx Lightning CHO cell lines, hitting 15+ g/L, backed by 24 approved products and 5 GMP trains up to 4,000 L.

  7. Unlock The Potential Of GPEx® Lightning: Accelerate Your HEK Cell Line Development 5/8/2026

    Cut HEK cell line development to four months with 30% higher titers. GPEx® Lightning delivers faster, scalable biologics manufacturing. Access the full summary now.

  8. The Growing Strategic Importance Of CDMOs In CGT 5/8/2026

    Discover how advanced manufacturing platforms, integrated analytics, and accelerated development strategies are helping overcome the scalability, supply chain, and operational challenges.

  9. Streamlining Process Characterization Toward Successful Validation Campaigns 5/8/2026

    Compress your biologics process characterization timeline without sacrificing quality. Learn how FMEA, DoE, and platform approaches help you hit PPQ readiness faster while managing regulatory risk.

  10. A Systematic Approach To Assess Biologics Developability 5/8/2026

    Discover how a systematic, data-driven developability workflow can accelerate biologic formulation development, identify risks earlier, and optimize stability and manufacturability.